Fig. 3.

Systemic anti-interleukin (IL)-10R1 monoclonal antibody (mAb) enhances intravesical bacillus Calmette–Guérin (BCG) treatment of bladder tumour. Groups of 20 mice were instilled intravesically (i.b.) with MB49-Luc cells and monitored for tumour growth by bioluminescent imaging. Eleven, 17 and nine mice developed bladder tumours in the three groups, respectively. Mice were treated i.b and intraperitoneal (i.p.) phosphate-buffered saline (PBS) for group 1, i.b. BCG (one-third strength) plus i.p. control rat immunoglobulin (Ig)G1 (200 μg/dose) for group 2 or i.b. BCG (one-third strength) plus i.p. anti-IL-10R1 mAb (200 μg/dose) for group 3 biweekly for a total of six treatments. Mice were followed for 76 days. Post-mortem bladders were weighed. Data are shown as mean ± standard deviation (s.d.) of bladder weights for each group (one bladder in group 3 was not recorded due to severe decay).